Deutsche Bank AG lifted its position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 23.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 52,493 shares of the company's stock after acquiring an additional 9,822 shares during the quarter. Deutsche Bank AG owned 0.11% of Omnicell worth $2,337,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the business. Smartleaf Asset Management LLC raised its holdings in shares of Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after purchasing an additional 273 shares in the last quarter. Johnson Financial Group Inc. acquired a new stake in shares of Omnicell during the 4th quarter valued at $37,000. Van ECK Associates Corp grew its holdings in shares of Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after acquiring an additional 315 shares in the last quarter. Headlands Technologies LLC acquired a new position in Omnicell in the 4th quarter worth about $53,000. Finally, First Horizon Advisors Inc. raised its stake in shares of Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after purchasing an additional 355 shares in the last quarter. Institutional investors own 97.70% of the company's stock.
Omnicell Stock Performance
Shares of NASDAQ:OMCL traded down $0.28 on Wednesday, hitting $29.33. The company had a trading volume of 57,452 shares, compared to its average volume of 588,979. The stock has a 50 day moving average price of $30.70 and a 200 day moving average price of $38.41. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of 109.04, a P/E/G ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 1-year low of $22.66 and a 1-year high of $55.74.
Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.16 by $0.10. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The firm had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. During the same period last year, the firm earned $0.03 EPS. The business's quarterly revenue was up 9.5% compared to the same quarter last year. Analysts expect that Omnicell, Inc. will post 1.09 EPS for the current year.
Analyst Upgrades and Downgrades
OMCL has been the subject of several recent analyst reports. Piper Sandler reaffirmed an "overweight" rating on shares of Omnicell in a report on Friday. JPMorgan Chase & Co. dropped their price objective on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Benchmark decreased their target price on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Wells Fargo & Company reiterated an "overweight" rating and set a $37.00 price target (up from $35.00) on shares of Omnicell in a report on Friday, May 23rd. Finally, Wall Street Zen upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a research note on Tuesday, May 20th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $44.83.
Check Out Our Latest Report on OMCL
About Omnicell
(
Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Read More
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
